NLBNPIT24I08 20241220 180 (P24I08) News

Form 4 - Statement of changes in beneficial ownership of securities

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock

Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio...

Recursion Announces Proposed Offering of Class A Common Stock

Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio...

Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Their Download Day

Recursion delivered multiple data packages to Bayer and initiated the first joint oncology project, which is...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144/A - Report of proposed sale of securities: [Amend]

Form 144 - Report of proposed sale of securities